Ultragenyx announces FDA accepts New Drug Application for UX007 (triheptanoin) for LC-FAOD
Ultragenyx announced the FDA has accepted for review the company’s NDA for UX007 (triheptanoin) for treatment of long-chain fatty acid oxidation disorders. The FDA has assigned a standard review designation with a Prescription Drug User Fee Act target date of July 31, 2020. October 14, 2019